Lars Wollung, Chairman, and Johanna Öberg, Board member and member of the audit committee, will leave RaySearch's Board on September 30, 2022. Both of them have time-consuming operational assignments and state these as the basis for the decision. The Board has decided to appoint Hans Wigzell as the new Chairman and also intends to recruit additional members. Lars Wollung will remain as an advisor during a transition period to ensure a satisfactory handover to the new Chairman.
"It has been an honor to participate in RaySearch's development of fascinating products to fight cancer. However, the assignment takes too much time and and then it is of course in the company’s best interests that I leave. I wish RaySearch all the best, with a brilliant development going forward," says Lars Wollung.
"It has been very exciting to work with RaySearch. Due to the expanded scope of my CEO assignment, I have chosen to cut back on Board involvement, but I wish the company, the management and my Board colleagues continued success in achieving the vision 'a world where cancer is conquered'," says Johanna Öberg.
Johan Löf, founder and CEO, RaySearch: "I would like to take the opportunity to thank Lars and Johanna for their work and commitment to RaySearch and wish them the best of luck in the future. I also look forward to working with Hans as Chairman. As a doctor, professor emeritus and former principal of KI, he covers a unique scope in medicine and medical technology. In addition, he has been part of RaySearch's Board since 2004 and knows the company very well.”
This information is information that RaySearch Laboratories AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out below, at 03:50 pm CEST on September 15, 2022.
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.
RaySearch software is used by over 800 clinics in more than 40 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.
* Subject to regulatory clearance in some markets.
For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
Björn Hårdemark, interim CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 709 564 217